Inclusion criteria: This phase II Lung-MAP treatment trial tests whether carboplatin and pemetrexed with or without selpercatinib works to shrink tumors in patients with RET fusion-positive NSCLC that is stage IV or has not responded to previous RET directed therapy.
SWOG PATIENT MATERIALS HERE https://www.swog.org/patients/trials-open-patients/adding-drug-selpercatinib-usual-treatment-ret-positive-advanced-non
Sponsor/Collaborator: Southwest Oncology Group|National Cancer Institute (NCI)
Contact and Locations:
Principal Investigator: Yasir Y Elamin,SWOG Cancer Research Network
Locations: https://clinicaltrials.gov/study/NCT05364645#contacts-and-locations
Mechanism of action: Selpercatinib, also known as LOXO-292, is a highly selective and potent, oral inhibitor for the treatment of patients with cancers that harbor abnormalities in the RET kinase.
Phases: Phase 2
NCT Number: NCT05364645
Status: Recruiting
